Drug Profile
Research programme: obesity therapies - Chong Kun Dang Pharmaceutical
Latest Information Update: 13 May 2010
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 10 Sep 2007 Preclinical trials in Obesity in South Korea (unspecified route)